N-(4-(2-chloropyrimidin-4-yl)phenyl)-N-(cyanomethyl)methanesulfonamide | 1056636-14-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(4-(2-chloropyrimidin-4-yl)phenyl)-N-(cyanomethyl)methanesulfonamide
• 英文别名: N-[4-(2-chloropyrimidin-4-yl)phenyl]-N-(cyanomethyl)methanesulfonamide
• CAS: 1056636-14-6
• 化学式: C₁₃H₁₁ClN₄O₂S
• 分子量: 322.775
• InChiKey: IYYUFBAUVQMREN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  95.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(4-(2-chloropyrimidin-4-yl)phenyl)-N-(cyanomethyl)methanesulfonamide 在 对甲苯磺酸 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 生成 5-(4-(4-(n-(cyanomethyl)methylsulfonamido)phenyl)pyrimidin-2-ylamino)-N-(2-(dimethylamino)ethyl)-2-morpholinobenzamide
  参考文献：
  名称：

  WO2008/109943

  摘要：

  公开号：
• 作为产物：
  描述：

  4-N-(甲基磺酰胺)苯硼酸 在 四(三苯基膦)钯 sodium carbonate 、 potassium carbonate 作用下， 以 丙醇 、 水 、 丙酮 、 甲苯 为溶剂， 反应 114.0h， 生成 N-(4-(2-chloropyrimidin-4-yl)phenyl)-N-(cyanomethyl)methanesulfonamide
  参考文献：
  名称：

  WO2008/109943

  摘要：

  公开号：

文献信息

• [EN] RETROMETABOLIC COMPOUNDS<br/>[FR] COMPOSÉS RÉTROMÉTABOLIQUES
  申请人：CYTOPIA RES PTY LTD

  公开号：WO2009029998A1

  公开（公告）日：2009-03-12

  The present invention relates to phenylaminopyrimidine compounds that are retrometabolic drugs or metabolites thereof. These compounds are also inhibitors of protein kinases including JAK kinases, in particular JAK2 kinases and can be used in the treatment of kinase associated diseases such as vascular diseases including pulmonary arterial hypertension (PAH), hypertension, hypertrophy and ischemia; immunological or inflammatory diseases including asthma and Chronic Obstructive Pulmonary Disease (COPD); and hyperproliferative diseases such as cancer including lung cancer.

  本发明涉及苯基氨基嘧啶化合物，它们是逆代谢药物或其代谢物。这些化合物也是蛋白激酶的抑制剂，包括JAK激酶，特别是JAK2激酶，并可用于治疗与激酶相关的疾病，如包括肺动脉高压（PAH）、高血压、肥大和缺血在内的血管疾病；免疫或炎症性疾病，如哮喘和慢性阻塞性肺病（COPD）；以及包括肺癌在内的增殖过度性疾病。
• PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：Burns Christopher John

  公开号：US20100197671A1

  公开（公告）日：2010-08-05

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

  本发明涉及苯基氨基嘧啶化合物，它们是蛋白激酶抑制剂，包括JAK激酶。特别是，这些化合物对JAK2激酶具有选择性。这些激酶抑制剂可用于治疗与激酶相关的疾病，如免疫和炎症性疾病，包括器官移植；增生性疾病，包括癌症和骨髓增生性疾病；病毒性疾病；代谢性疾病；以及血管性疾病。
• Phenyl amino pyrimidine compounds and uses thereof
  申请人：Burns Christopher John

  公开号：US08486941B2

  公开（公告）日：2013-07-16

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

  本发明涉及苯基氨基嘧啶化合物，这些化合物是蛋白激酶（包括JAK激酶）的抑制剂。特别地，这些化合物对JAK2激酶具有选择性。这些激酶抑制剂可用于治疗与激酶相关的疾病，如免疫和炎症性疾病，包括器官移植；高增殖性疾病，包括癌症和骨髓增生性疾病；病毒性疾病；代谢性疾病；以及血管性疾病。
• Phenyl Amino Pyrimidine Compounds and Uses Thereof
  申请人：Sierra Oncology, Inc.

  公开号：US20220388967A1

  公开（公告）日：2022-12-08

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
• US8486941B2
  申请人：——

  公开号：US8486941B2

  公开（公告）日：2013-07-16